Eloralintide Research Peptide (RUO)

What is Eloralintide?

Eloralintide is a long-acting, selective amylin receptor agonist (also referenced in the literature as LY3841136) in clinical development for obesity and weight management. It is a 37-amino-acid, C-terminally amidated peptide engineered for receptor selectivity and metabolic stability: two cysteine residues are joined through a methylene-thioacetal bridge, non-coded residues are incorporated within the chain, and a lysine is acylated with a γGlu-γGlu spacer linked to a C20 fatty di-acid for albumin binding and extended half-life. Mechanistically it acts as an agonist at the amylin receptor family, preferentially activating the amylin-1 receptor (AMY1R) over the calcitonin receptor, an action associated with satiety signalling.

As a chemical substance, eloralintide (CAS 2883634-40-8, molecular formula C201H319N49O65S2, ~4526.10 g/mol) is typically handled as a lyophilised powder. It is investigational, in clinical development and not yet approved by the US FDA, EMA or other major regulators for therapeutic use.

How Eloralintide Is Produced & Characterised

Eloralintide is a synthetically demanding peptide: the 37-mer length, the internal methylene-thioacetal cyclisation, the non-coded residues and the C20 di-acid side-chain conjugation all create opportunities for deletion sequences, diastereomers, incomplete cyclisation and incomplete acylation. Across the industry, peptides of this class are generally assembled by optimised Fmoc solid-phase peptide synthesis (SPPS) with controlled cyclisation and side-chain conjugation, followed by purification on preparative dynamic axial compression (DAC) HPLC columns that resolve the target sequence from closely related impurities.

For reproducible material, processes are typically optimised for batch-to-batch consistency from milligram optimisation runs through gram and kilogram quantities, with the final product lyophilised to a stable, uniform powder. Process development, technology transfer and scale-up are the usual stages by which such a candidate progresses from early research through clinical supply to larger volumes.

Regulatory & Documentation Context

Because eloralintide is investigational and not yet approved, programmes that use it generally rely on CMC documentation to support regulatory filings for investigational medicines. For a candidate at this stage that typically includes CTD Module 3 CMC sections (for IND/IMPD referencing), analytical validation packages aligned to ICH Q2(R1), and stability data; a US-DMF dossier may follow as a programme advances.

Quality systems for investigational APIs are generally framed around inspection readiness aligned to FDA, EMA and PMDA expectations. As eloralintide is investigational and not yet approved for therapeutic use, no efficacy, therapeutic-benefit or prescribing claims can be made about it. Nothing on this page is medical or prescribing advice.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Eloralintide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Eloralintide in their country.